To accomplish the above-described objective, provided are a pharmaceutical composition for inhibiting tolerance of a targeted anti-cancer agent, anti-cancer supplements and the like comprising, as active ingredients, one or more selected from the group consisting of integrin β3 neutralizing antibody, integrin β3 siRNA, an Src inhibitor and Src siRNA. When the pharmaceutical composition of the present invention is used as a combined therapy with conventional targeted anti-cancer agents, the effects of anti-cancer treatment may be increased. Moreover, the composition of the present invention is expected to be used in the development of a targeted anti-cancer agent with respect to integrin β3.Afin de réaliser lobjectif susmentionné, à savoir de surmonter une tolérance vis-à-vis dun agent anticancéreux ciblé, linvention propose une composition pharmaceutique permettant dinhiber une tolérance vis-à-vis dun agent anticancéreux ciblé, de compléments anticancéreux et similaires qui contiennent, comme ingrédients actifs, un ou plusieurs éléments choisis dans le groupe comprenant un anticorps neutralisant lintégrine β3, lARNsi de lintégrine β3, un inhibiteur Src et lARNsi de Src. Lorsque la composition pharmaceutique de la présente invention est utilisée en multithérapie avec des agents anticancéreux ciblés traditionnels, les effets du traitement anticancéreux peuvent être accrus. En outre, la composition de la présente doit être utilisée dans le développement dun agent anticancéreux ciblé prenant en compte lintégrine β3.상기의 목적을 달성하기 위하여, 본 발명은 인테그린 β3 중화항체, 인테그린 β3 siRNA, Src 억제제 및 Src siRNA로 이루어진 군에서 선택되는 하나 이상을 유효성분으로 포함하는 표적 항암제 내성 억제용 약학적 조성물, 항암 보조제 등을 제공한다. 본 발명의 약학적 조성물을 종래 표적 항암제로 병용 투여할 경우, 항암치료효과를 증가시킬 수 있다. 이에 더하여, 본 발명은 인테그린 β3에 대한 표적 항암제 개발에 이용될 수 있을 것으로 기대된다.
